EE356 Budget Impact Analysis on Blinatumomab for the Treatment of Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R BCP-ALL)
Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.604
https://www.valueinhealthjournal.com/article/S1098-3015(22)00805-1/fulltext
Title :
EE356 Budget Impact Analysis on Blinatumomab for the Treatment of Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R BCP-ALL)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00805-1&doi=10.1016/j.jval.2022.04.604
First page :
Section Title :
Open access? :
No
Section Order :
10539